Ruth Seggewiss‐Bernhardt
- Oncology top 10%
- CAR-T cell therapy research 5
- Genetics top 10%
-
- Immune Cell Function and Interaction 8
- T-cell and B-cell Immunology 4
- Hematology top 10%
- Multiple Myeloma Research and Treatments 2
- Chronic Myeloid Leukemia Treatments 2
- Hematopoietic Stem Cell Transplantation 2
-
- PI3K/AKT/mTOR signaling in cancer 4
-
- Advanced Breast Cancer Therapies 3
- Co-authors
- Douglas BootleMartin SchülerMarta Gil-MartínCornelia QuadtDavid DemanseDejan JuricJosé BaselgaHoward A. Burris
- Cited by
- OncologyGeneticsImmunology
- Partner nations
- GermanyUnited StatesSpain
In The Last Decade
Ruth Seggewiss‐Bernhardt
18 papers receiving 876 citations
Hit Papers
Peers
Comparison fields: 5 of 69
- Oncology 409
- Genetics 152
- Immunology 214
- Hematology 87
- Cancer Research 114
Countries citing papers authored by Ruth Seggewiss‐Bernhardt
This map shows the geographic impact of Ruth Seggewiss‐Bernhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Seggewiss‐Bernhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Seggewiss‐Bernhardt more than expected).
Fields of papers citing papers by Ruth Seggewiss‐Bernhardt
This network shows the impact of papers produced by Ruth Seggewiss‐Bernhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Seggewiss‐Bernhardt. The network helps show where Ruth Seggewiss‐Bernhardt may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ruth Seggewiss‐Bernhardt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2021 | 22 | |
| 3 | 2021 | 1 | |
| 4 | 2020 | 1 | |
| 5 | Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Studybreakdown → | 2018 | 302 |
| 6 | 2018 | 186 | |
| 7 | 2018 | 23 | |
| 8 | 2018 | 138 | |
| 9 | 2017 | 4 | |
| 10 | 2017 | 21 | |
| 11 | 2015 | 3 | |
| 12 | 2015 | 52 | |
| 13 | 2014 | 9 | |
| 14 | 2013 | 19 | |
| 15 | 2013 | 12 | |
| 16 | 2013 | 5 | |
| 17 | 2012 | 37 | |
| 18 | 2012 | 33 | |
| 19 | 2012 | 21 |
About Ruth Seggewiss‐Bernhardt
Ruth Seggewiss‐Bernhardt is a scholar working on Hematology, Immunology and Oncology, having authored 19 papers that have together received 889 indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (8 papers), CAR-T cell therapy research (5 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), T-cell and B-cell Immunology (4 papers), Advanced Breast Cancer Therapies (3 papers), Multiple Myeloma Research and Treatments (2 papers), Chronic Myeloid Leukemia Treatments (2 papers) and Hematopoietic Stem Cell Transplantation (2 papers). The work is most often cited by research in Oncology (409 citations), Genetics (152 citations) and Immunology (214 citations). Ruth Seggewiss‐Bernhardt has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include Douglas Bootle, Martin Schüler, Marta Gil-Martín, Cornelia Quadt, David Demanse, Dejan Juric, José Baselga, Howard A. Burris, Jordi Rodón and Alan Huang. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.